U.S. Consumer Finance Stock News

If you have ever looked at Generac Holdings and wondered whether the current share price really reflects its long term potential, you are not alone. This article is designed to unpack exactly that question. After a choppy run, the stock is down 13.6% over the last week and 11.1% over the past year, but still sits about 50.7% higher than three years ago. This hints at a story that is more complicated than a simple up or down trend. Recently, investors have been weighing Generac's positioning...

Albertsons Companies (ACI) is under fresh scrutiny after the FDA cited the grocer for leaving recalled ByHeart infant formula linked to a botulism outbreak on shelves, raising clear questions about recall controls and compliance. See our latest analysis for Albertsons Companies. The FDA letter lands at a tricky time for Albertsons, with a 1 year to date share price return of negative 11.34 percent and a 1 year total shareholder return of negative 8.03 percent, signaling fading near term...

Wondering if Amdocs is quietly turning into a value opportunity while everyone is chasing the latest hype stock? You are not alone, and this is exactly what we are going to unpack. Despite a choppy year where the share price is down 4.4% year to date and 5.3% over the last 12 months, the stock has started to firm up recently, with a 1.4% gain over the past week and 6.8% over the last month. Much of this price action has been shaped by ongoing contract wins and renewals with major telecom...

If you are wondering whether Coinbase Global at around $245 a share is still a smart way to get exposure to the crypto ecosystem, or if most of the upside is already priced in, this article will walk you through the real valuation story behind the ticker. Despite a rough recent patch, with the stock down 8.4% over the last week, 4.7% over the past month, and 12.1% over the past year, Coinbase is still up an eye-catching 590.7% over three years, which keeps growth-minded investors watching...

Bullish (BLSH) has been climbing recently, with the stock up about 4% on the day and roughly 23% over the past month, even as its year to date performance remains sharply negative. See our latest analysis for Bullish. That recent 1 month share price return of about 23% looks more like a sharp rebound than a steady trend. This is especially true when set against a year to date share price return that is still deeply negative, so momentum is improving but not yet proven. If Bullish has piqued...

Marathon Petroleum (MPC) is back in focus after naming Maria A. Khoury as its next Chief Financial Officer, a leadership move that could subtly reshape how investors think about the stock. See our latest analysis for Marathon Petroleum. The CFO announcement lands after a choppy stretch, with a roughly 14% 1 month share price return decline from about $195 to $168.32, even as the 1 year total shareholder return of 29% and 5 year total shareholder return of 365.55% still point to strong long...

Rosenblatt recently initiated coverage of Taboola.com with a positive rating, highlighting the company’s AI-powered content discovery and native advertising platform that competes with major digital ad players. This endorsement comes soon after Taboola reported quarterly results that surpassed expectations and issued an upbeat outlook, reinforcing interest in its differentiated open-web advertising model. With that as context, we’ll explore how Rosenblatt’s new coverage reinforces Taboola’s...

Applied Materials recently announced that its Board of Directors approved a quarterly cash dividend of US$0.46 per share, payable on March 12, 2026 to shareholders of record on February 19, 2026, alongside record fiscal 2025 results and higher capital spending plans for 2026. At the same time, a wave of positive analyst research highlighting AI-driven semiconductor equipment demand, advanced packaging leadership, and resilient margins has reinforced Applied Materials’ role at the center of...

DRDGOLD (NYSE:DRD) has flagged impending strike action at its ERGO operations from 18 December, as unions push back on wages and profit sharing. This is putting near term output and margins under closer scrutiny. See our latest analysis for DRDGOLD. Even with the strike risk grabbing headlines, DRDGOLD’s strong year to date 246.34% share price return, alongside a 261.47% one year total shareholder return, suggests momentum is still firmly on the upside as investors weigh higher operational...

Vornado Realty Trust (VNO) has quietly slipped over the past week and is down sharply over the past 3 months, prompting investors to recheck whether this office focused REIT still matches their risk appetite. See our latest analysis for Vornado Realty Trust. The recent slide adds to a tougher year, with the latest share price of $33.37 reflecting weaker short term share price returns, while the three year total shareholder return of 66.16% shows the longer term rebound story is still...

If you are wondering whether Charles Schwab is still attractively priced today or if most of the potential upside has already been realized, this breakdown will help clarify what you are really paying for. The stock has been on a solid run, up 2.2% over the last week, 6.7% over the past month, and 33.8% year to date, with a 34.6% gain over the last year and 102.6% over five years, reshaping how the market views its risk and growth profile. Recent headlines have focused on Schwab’s continued...

If you are wondering whether Novo Nordisk is still worth buying after its blockbuster run in recent years, you are not alone. This article will walk through whether the current price really makes sense. Despite long term gains of 47.2% over five years, the stock has pulled back recently, with returns of -4.2% over the last week, -1.9% over the last month, and a much steeper -45.1% year to date. These moves come as investors weigh Novo Nordisk's continued dominance in diabetes and obesity...

L3Harris Technologies (LHX) just landed an up to $843 million Space Development Agency contract to build 18 infrared tracking satellites, along with a fresh upgrade from Morgan Stanley, prompting investors to reassess the stock’s potential. See our latest analysis for L3Harris Technologies. That backdrop helps explain why the share price has climbed strongly this year, with a year to date share price return of 38.62% and a five year total shareholder return of 71.88%, suggesting momentum is...

Wondering if Pitney Bowes is still a bargain after its big run, or if the easy money has already been made? You are not alone, and that is exactly what we are going to unpack here. The stock is now trading around $10.62, up 3.8% over the last week, 12.0% over the past month, and 47.1% year to date, building on 51.3% returns over 1 year and 216.0% over 3 years. Those gains have come as investors have warmed to Pitney Bowes transformation story and shifting mix toward higher margin, tech...

Humana (HUM) just outlined a multi year leadership handoff in its core insurance arm, as long time Insurance Segment President George Renaudin prepares to retire and Amazon veteran Aaron Martin steps in to reshape Medicare Advantage. See our latest analysis for Humana. The leadership shake up lands as Humana’s share price has climbed about 13 percent over the past month to 259.40 dollars, even though its three year total shareholder return remains deeply negative. This suggests investors are...

International General Insurance Holdings (IGIC) is back on investors radar after RBC Capital resumed coverage with a positive view on its long term prospects and disciplined underwriting in a softening insurance market. See our latest analysis for International General Insurance Holdings. The renewed Outperform calls have arrived as IGIC edges higher, with a 7 day share price return of 3.87 percent and a 1 month share price return of 7.31 percent. This suggests momentum is quietly building on...

Recent analysis suggests Xeris Biopharma Holdings (XERS) is shifting from survival mode to a profit focused specialty pharma story, with three commercial drugs and a growing pipeline reshaping how investors view the stock. See our latest analysis for Xeris Biopharma Holdings. That improving story is already showing up in the tape, with the share price at $7.34 after a 1 day share price return of 4.71 percent and a powerful year to date share price return of 112.14 percent. The 3 year total...

Hecla Mining (HL) has suddenly jumped onto more watchlists after a banner year, with record results, strong silver prices, and an upcoming move into the S&P MidCap 400 that is putting the stock squarely in focus. See our latest analysis for Hecla Mining. That surge is not happening in a vacuum, with a roughly 273.95% year to date share price return and a 291.14% one year total shareholder return reflecting powerful momentum as record results, index inclusion and unusual options activity reset...

Toro (TTC) just delivered a quarter that cleared Wall Street’s bar, leaned on its Professional segment to do the heavy lifting, and paired the beat with upbeat guidance, dividend growth, and fresh buyback firepower. See our latest analysis for Toro. At a latest share price of $77.67, Toro has enjoyed a 1 month share price return of 13.07%, even though its 1 year total shareholder return of negative 2.71% and 3 year total shareholder return of negative 27.74% show a longer term reset in...

For investors wondering whether Under Armour at around $4.50 is a beaten-down bargain or a value trap, this breakdown outlines what the market might be overlooking. Despite a difficult longer term track record, with the share price still down 44.1% year to date and 74.0% over five years, the stock has recently bounced 4.6% over the last week and 7.1% over the last month, prompting some investors to revisit the story. Recent headlines have highlighted Under Armour refreshing its product...

Travelers Companies (TRV) has been quietly rewarding patient shareholders, with the stock up about 6% over the past 3 months and roughly 24% in the past year, handily outpacing the broader market. See our latest analysis for Travelers Companies. With the latest share price around $292.92 and a solid year to date share price return of 21.6%, Travelers’ steady climb suggests investors are growing more comfortable with its earnings power and underwriting discipline. If you are reassessing your...

Moderna (MRNA) just saw its shares climb after CEPI agreed to provide up to $54.3 million to support advancing its H5 bird flu vaccine, mRNA-1018, into a pivotal Phase 3 trial. See our latest analysis for Moderna. The CEPI funding has turbocharged what was already a sharp rebound, with a 30 day share price return of 51.16 percent and a 90 day share price return of 33.91 percent. However, the one year total shareholder return of negative 14.19 percent shows investors are still in recovery mode...

If you are wondering whether AST SpaceMobile is still a smart bet after its huge run up, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has been on a wild ride, up about 30.7% over the last month, 250.5% year to date and an eye catching 1810.3% over three years, even with a small 1.1% dip in the past week. Those moves have been fueled by excitement around AST SpaceMobile's plan to build a space based cellular broadband network that...

Wondering if AppFolio at around $233 a share is still a smart buy, or if most of the upside is already priced in? Let us break down what the market might be implying about its long term potential. Despite being down 5.8% year to date and 7.2% over the last year, the stock has still delivered a 123.5% return over 3 years and 29.4% over 5 years, which shows that investors have rewarded the story over time, even if momentum has cooled recently. Recent interest has centered on AppFolio's...